About ELEKTA (NASDAQ:EKTAY)
Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; Monaco, a treatment planning system; Venezia, an applicator for treating gynecological cancer; and METRIQ, a cancer registry data solution. It also offers installation, implementation, training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:EKTAY
- CUSIP: N/A
- Web: www.elekta.com
- Market Cap: $3.7 billion
- Outstanding Shares: 368,588,000
- 50 Day Moving Avg: $10.31
- 200 Day Moving Avg: $9.85
- 52 Week Range: $7.97 - $11.18
Sales & Book Value:
- Trailing P/E Ratio: 156.210
- Foreward P/E Ratio: 24.83
- P/E Growth: 0.000
- Annual Revenue: $1.38 billion
- Price / Sales: 2.59
- Book Value: $2.15 per share
- Price / Book: 4.52
- Average Volume: 5,666 shs.
Frequently Asked Questions for ELEKTA (NASDAQ:EKTAY)
What is ELEKTA's stock symbol?
ELEKTA trades on the NASDAQ under the ticker symbol "EKTAY."
How often does ELEKTA pay dividends? What is the dividend yield for ELEKTA?
ELEKTA declared a None dividend on Thursday, July 20th. Shareholders of record on Friday, August 25th will be paid a dividend of $0.04 per share on Thursday, September 14th. The ex-dividend date is Wednesday, August 23rd. View ELEKTA's Dividend History.
How were ELEKTA's earnings last quarter?
ELEKTA (NASDAQ:EKTAY) announced its quarterly earnings data on Wednesday, December, 4th. The company reported $0.07 EPS for the quarter. View ELEKTA's Earnings History.
When will ELEKTA make its next earnings announcement?
Who are some of ELEKTA's key competitors?
Some companies that are related to ELEKTA include West Pharmaceutical Services (WST), bluebird bio (BLUE), Bio-Rad Laboratories (BIO), BIOVERATIV INC (BIVV), TESARO (TSRO), Icon Plc (ICLR), Dr. Reddy's Laboratories Ltd (RDY), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), Envision Healthcare Corporation (EVHC), Hill-Rom Holdings (HRC), Neurocrine Biosciences (NBIX), PRA Health Sciences (PRAH), United Therapeutics Corporation (UTHR), Juno Therapeutics (JUNO), Premier (PINC) and Medidata Solutions (MDSO).
How do I buy ELEKTA stock?
Shares of ELEKTA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ELEKTA's stock price today?
MarketBeat Community Rating for ELEKTA (NASDAQ EKTAY)MarketBeat's community ratings are surveys of what our community members think about ELEKTA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ELEKTA stock can currently be purchased for approximately $9.69.
Consensus Ratings for ELEKTA (NASDAQ:EKTAY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating|
|Consensus Rating:||Sell (Score: 1.00)|
|Consensus Price Target: ||N/A|Consensus Price Target History for ELEKTA (NASDAQ:EKTAY)
Analysts' Ratings History for ELEKTA (NASDAQ:EKTAY)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|12/7/2016||Jefferies Group LLC||Downgrade||Hold -> Underperform||N/A|
|12/8/2015||Morgan Stanley||Downgrade||Equal Weight -> Underweight||N/A|
Earnings History for ELEKTA (NASDAQ:EKTAY)Earnings History by Quarter for ELEKTA (NASDAQ EKTAY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/26/2017|| || || || || || || || |
Earnings Estimates for ELEKTA (NASDAQ:EKTAY)
Current Year EPS Consensus Estimate: $0.330 EPS
Next Year EPS Consensus Estimate: $0.390 EPS
Dividend History by Quarter for ELEKTA (NASDAQ EKTAY)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for ELEKTA (NASDAQ:EKTAY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ELEKTA (NASDAQ:EKTAY)
Latest Headlines for ELEKTA (NASDAQ:EKTAY)
ELEKTA (EKTAY) Chart for Saturday, October, 21, 2017